Huaheng Biotech's 2026 interim net profit was 101 million yuan, down 12.22% year-on-year

Earnings
โดย Jiemian·CN·Read original
Summary · why it matters

Huaheng Biotech released its 2026 interim report, with net profit attributable to the parent company of 101 million yuan, a decrease of 12.22% compared with the same period last year. The company's total operating revenue was 1.632 billion yuan, and net cash inflow from operating activities was 74.4052 million yuan, down 0.44% year-on-year. The company's latest asset-liability ratio was 56.32%, gross margin was 23.59%, ROE was 3.73%, and diluted earnings per share was 0.40 yuan.

Impact on stocks 1

Others▼ · 1 stocks
© 2026 MarketDXNews